On June 24, 2025, analyst Maury Raycroft from Jefferies initiated coverage on Cardiff Oncology (CRDF, Financial). The analytical coverage comes with a "Hold" rating, indicating a neutral stance on the company's stock performance in the stock market.
Jefferies announced a price target for Cardiff Oncology (CRDF, Financial) at USD 3.50. This is the initial price target set by the firm, as there was no prior target established. The current target suggests Jefferies sees limited near-term upside from the current levels.
The coverage by Jefferies provides insight into the market's outlook on CRDF, reflecting a cautious approach in the current financial landscape. The "Hold" rating indicates that investors and market participants might consider maintaining their positions rather than buying or selling aggressively at this point.
Cardiff Oncology (CRDF, Financial), listed on the NASDAQ, is closely watched by investors, and the initiation of coverage by Jefferies could play a significant role in shaping investment decisions. With the detailed analysis from Jefferies, stakeholders now have additional data points to consider when evaluating the potential future performance of CRDF in the stock market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Cardiff Oncology Inc (CRDF, Financial) is $12.58 with a high estimate of $20.00 and a low estimate of $3.50. The average target implies an upside of 298.21% from the current price of $3.16. More detailed estimate data can be found on the Cardiff Oncology Inc (CRDF) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Cardiff Oncology Inc's (CRDF, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cardiff Oncology Inc (CRDF, Financial) in one year is $2.83, suggesting a downside of 10.44% from the current price of $3.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cardiff Oncology Inc (CRDF) Summary page.
